Needham & Company LLC Issues Pessimistic Forecast for CorMedix (NASDAQ:CRMD) Stock Price

CorMedix (NASDAQ:CRMD) had its target price decreased by research analysts at Needham & Company LLC from $16.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 96.59% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Zacks Research upgraded shares of CorMedix from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 4th. Truist Financial set a $16.00 target price on shares of CorMedix in a research report on Thursday. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of CorMedix in a report on Thursday. D Boral Capital upgraded shares of CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, HC Wainwright boosted their price objective on shares of CorMedix from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $17.86.

CorMedix Stock Performance

Shares of CRMD opened at $7.63 on Thursday. The company has a current ratio of 1.94, a quick ratio of 1.73 and a debt-to-equity ratio of 0.39. The firm has a market cap of $601.17 million, a PE ratio of 3.70 and a beta of 1.36. CorMedix has a 12 month low of $5.60 and a 12 month high of $17.43. The stock has a fifty day moving average price of $10.96 and a 200-day moving average price of $11.62.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The company had revenue of $104.28 million for the quarter, compared to analyst estimates of $65.63 million. During the same period in the prior year, the company posted ($0.05) EPS. The firm’s quarterly revenue was up 810.2% compared to the same quarter last year. Equities research analysts predict that CorMedix will post -0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at CorMedix

In related news, CEO Joseph Todisco sold 30,000 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total transaction of $360,000.00. Following the completion of the transaction, the chief executive officer owned 509,496 shares of the company’s stock, valued at $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan W. Dunton sold 20,000 shares of the company’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total transaction of $260,000.00. Following the completion of the sale, the director directly owned 40,250 shares in the company, valued at approximately $523,250. The trade was a 33.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 90,000 shares of company stock worth $1,095,200. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of CorMedix

Several hedge funds and other institutional investors have recently bought and sold shares of CRMD. SG Americas Securities LLC raised its position in CorMedix by 38.6% during the fourth quarter. SG Americas Securities LLC now owns 28,182 shares of the company’s stock valued at $328,000 after acquiring an additional 7,849 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of CorMedix by 35.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 302,508 shares of the company’s stock valued at $3,518,000 after purchasing an additional 78,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of CorMedix by 6.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 27,540 shares of the company’s stock valued at $310,000 after purchasing an additional 1,707 shares during the period. Gryphon Financial Partners LLC acquired a new position in shares of CorMedix in the 4th quarter valued at $300,000. Finally, JPMorgan Chase & Co. boosted its holdings in CorMedix by 176.7% during the third quarter. JPMorgan Chase & Co. now owns 97,228 shares of the company’s stock worth $1,131,000 after buying an additional 62,085 shares in the last quarter. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix News Summary

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Analyst support remains: D. Boral Capital reaffirmed a “buy” rating with a $14 target, and Needham maintained a buy rating despite trimming its target from $16 to $15 — these endorsements help provide demand support for the shares. Analyst notes
• Positive Sentiment: Management continuity: CEO Joseph Todisco signed an extended employment contract and will add the Chairman role while the prior chair moves to Lead Independent Director — the move signals board-level continuity during the reset. Leadership update
• Neutral Sentiment: Investor outreach / visibility: Management will present a corporate overview at the J.P. Morgan Healthcare Conference (Jan 12), which could provide additional color and catalyze trading flows depending on guidance detail and Q&A. JPM presentation
• Neutral Sentiment: Valuation / bullish commentary: Coverage pieces (Zacks, Yahoo analysis) argue the stock may be undervalued or worth reassessing after the recent operational reset; these are watch items but not immediate catalysts. Zacks coverage
• Negative Sentiment: Material FY-2026 guidance reset: Management trimmed FY-2026 revenue guidance to $300–$320M versus consensus (~$445M), creating a large miss expectation and driving heavy selling pressure. Guidance cut article
• Negative Sentiment: Preliminary results and reduced outlook triggered downside: Q4/FY-2025 preliminary numbers were reported but the updated FY-2026 revenue range and related messaging prompted immediate negative investor reaction and headlines about a stock crash. Preliminary results
• Negative Sentiment: Reimbursement risk flagged: Analysis notes emerging CMS reimbursement headwinds that could pressure future revenue realization and margins — this is a structural risk that could sustain downward pressure if unresolved. CMS reimbursement analysis

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.